Diagnostic and therapeutic methods for cancer
AssigneeGenentech, Inc.
InventorsZia KHAN, Matthew Lawrence ALBERT, G Scott CHANDLER
Life of this patent
Estimating the term…
Abstract
Provided herein are diagnostic and therapeutic methods for the treatment of cancer using polygenic risk scores (PRSs) for dermatological autoimmune diseases. In particular, the invention provides methods for patient selection and methods of treatment.
Claims86
A method of identifying an individual having a cancer who may benefit from a treatment comprising an immune checkpoint inhibitor, the method comprising determining a polygenic risk score (PRS) for one or more of vitiligo, psoriasis, and atopic dermatitis from a sample from the individual, wherein:
- (a) a PRS for vitiligo that is above a vitiligo reference PRS identifies the individual as one who may benefit from a treatment comprising an immune checkpoint inhibitor;
- (b) a PRS for psoriasis that is above a psoriasis reference PRS identifies the individual as one who may benefit from a treatment comprising an immune checkpoint inhibitor;
- or
- (c) a PRS for atopic dermatitis that is below an atopic dermatitis reference PRS identifies the individual as one who may benefit from a treatment comprising an immune checkpoint inhibitor.
A method for selecting a therapy for an individual having a cancer, the method comprising determining a PRS for vitiligo or psoriasis from a sample from the individual, wherein a PRS for vitiligo that is above a vitiligo reference PRS or a PRS for psoriasis that is above a psoriasis reference PRS identifies the individual as one who may benefit from a treatment comprising an immune checkpoint inhibitor.
A method for selecting a therapy for an individual having a cancer, the method comprising determining a PRS for atopic dermatitis from a sample from the individual, wherein a PRS for atopic dermatitis from the sample that is below an atopic dermatitis reference PRS identifies the individual as one who may benefit from a treatment comprising an immune checkpoint inhibitor.
A method of treating an individual having a cancer, the method comprising:
- (a) determining a PRS for one or more of vitiligo, psoriasis, and atopic dermatitis from a sample from the individual, wherein:
- (i) the PRS for vitiligo from the sample is above a vitiligo reference PRS;
- (ii) the PRS for psoriasis from the sample is above a psoriasis reference PRS;
- or
- (iii) the PRS for atopic dermatitis from the sample is below an atopic dermatitis reference PRS;
- and
- (b) administering an effective amount of an immune checkpoint inhibitor to the individual.
A method of treating an individual having a cancer, the method comprising administering an immune checkpoint inhibitor to the individual who has been determined to:
- (a) have a PRS for vitiligo that is above a vitiligo reference PRS;
- (b) have a PRS for psoriasis that is above a psoriasis reference PRS;
- or
- (c) have a PRS for atopic dermatitis that is below an atopic dermatitis reference PRS.
An immune checkpoint inhibitor for use in treating an individual having a cancer who has been identified as one who may benefit from a treatment comprising an immune checkpoint inhibitor based on:
- (a) a PRS for vitiligo from a sample from the individual that is above a vitiligo reference PRS;
- (b) a PRS for psoriasis from a sample from the individual that is above a psoriasis reference PRS;
- or
- (c) a PRS for atopic dermatitis from a sample from the individual that is below an atopic dermatitis reference PRS.
Use of an immune checkpoint inhibitor in the manufacture of a medicament for treating an individual having a cancer who has been identified as one who may benefit from a treatment comprising an immune checkpoint inhibitor based on:
- (a) a PRS for vitiligo that is above a vitiligo reference PRS;
- (b) a PRS for psoriasis that is above a psoriasis reference PRS;
- or
- (c) a PRS for atopic dermatitis that is below an atopic dermatitis reference PRS.
Dependencies are inferred from the claim text.